XNK Therapeutics names new CFO
16 September 2022 -

XNK Therapeutics AB ('XNK'), a clinical stage, immunotherapy company focusing on cancer treatment by developing novel NK cell-based therapies, announced on Thursday that it has named Dr Anna-Karin Maltais as its new chief scientific officer, effective 17 October.

Dr Maltais is to serve as a member of the company's management team.

In the new role, Dr Maltais will oversee development and implementation of the company's scientific strategy.

Dr Maltais has previously led R&D activities and strategies within several organizations. Most recently Dr Maltais has served as Head of CMC, Biotech Research and Product Development, Global Rare Diseases at Chiesi Farmaceutici SpA.